ES2164883T3 - Compuestos y metodos para la diagnosis de la leishmaniasis. - Google Patents

Compuestos y metodos para la diagnosis de la leishmaniasis.

Info

Publication number
ES2164883T3
ES2164883T3 ES96912940T ES96912940T ES2164883T3 ES 2164883 T3 ES2164883 T3 ES 2164883T3 ES 96912940 T ES96912940 T ES 96912940T ES 96912940 T ES96912940 T ES 96912940T ES 2164883 T3 ES2164883 T3 ES 2164883T3
Authority
ES
Spain
Prior art keywords
compounds
leishmaniasis
leishmania
useful
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96912940T
Other languages
English (en)
Inventor
Steven G Reed
Yasir A W Skeiky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of ES2164883T3 publication Critical patent/ES2164883T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/822—Protozoa

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Testing, Inspecting, Measuring Of Stereoscopic Televisions And Televisions (AREA)
  • Semiconductor Integrated Circuits (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE DESCRIBEN COMPUESTOS Y PROCEDIMIENTOS PARA DIAGNOSTICAR LA INFECCION POR LEISHMANIA. LOS COMPUESTOS DESCRITOS INCLUYEN POLIPEPTIDOS QUE CONTIENEN AL MENOS UN EPITOPO DEL ANTIGENO RIBOSOMICO ACIDO DE LEISHMANIA CHAGASI LCPO, O UN VARIANTE DEL MISMO. ESTOS COMPUESTOS RESULTAN UTILES EN UNA DIVERSIDAD DE INMUNOENSAYOS PARA DETECTAR LA INFECCION POR LEISHMANIA Y PARA IDENTIFICAR INDIVIDUOS CON INFECCIONES ASINTOMATICAS QUE PROBABLEMENTE PUEDEN PROGRESAR HACIA UNA LEISHMANIASIS VISCERAL AGUDA. LOS COMPUESTOS POLIPEPTIDICOS ADEMAS RESULTAN UTILES EN VACUNAS Y COMPOSICIONES FARMACEUTICAS PARA EVITAR LA LEISHMANIASIS.
ES96912940T 1995-04-21 1996-04-19 Compuestos y metodos para la diagnosis de la leishmaniasis. Expired - Lifetime ES2164883T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/428,414 US5912166A (en) 1995-04-21 1995-04-21 Compounds and methods for diagnosis of leishmaniasis

Publications (1)

Publication Number Publication Date
ES2164883T3 true ES2164883T3 (es) 2002-03-01

Family

ID=23698799

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96912940T Expired - Lifetime ES2164883T3 (es) 1995-04-21 1996-04-19 Compuestos y metodos para la diagnosis de la leishmaniasis.

Country Status (9)

Country Link
US (1) US5912166A (es)
EP (2) EP0824699B1 (es)
AT (1) ATE208500T1 (es)
AU (1) AU5559496A (es)
BR (1) BR9608016A (es)
DE (1) DE69616777D1 (es)
ES (1) ES2164883T3 (es)
PT (1) PT824699E (es)
WO (1) WO1996033414A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613337B1 (en) 1997-02-12 2003-09-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6375955B1 (en) * 1995-09-22 2002-04-23 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6638517B2 (en) 1995-09-22 2003-10-28 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6500437B1 (en) 1995-09-22 2002-12-31 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6607731B1 (en) 1995-09-22 2003-08-19 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6365165B1 (en) 1995-09-22 2002-04-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
EP0981624A2 (en) * 1997-02-12 2000-03-01 Corixa Corporation $i(LEISHMANIA) ANTIGENS FOR USE IN THE THERAPY AND DIAGNOSIS OF LEISHMANIASIS
ES2133236B1 (es) * 1997-06-27 2000-04-16 Leti Lab Gen quimerico formado por las secuencias de dna que codifican los determinantes antigenicos de cuatro proteinas de l. infantum, aplicable para el diagnostico serologico de leishmaniosis canina y proteina obtenida.
SI1141305T1 (sl) * 1998-12-23 2006-10-31 Leti Lab Himerni gen, ki kodira antigenske determinante stirih proteinov L. Infantum
PT1141305E (pt) * 1998-12-23 2006-10-31 Leti Lab Gene quimerico formado pelas sequencias de adn que codifica os determinantes antigenicos de quatro proteinas de l. infantum
US6972198B2 (en) 1999-02-26 2005-12-06 Cyclacel, Ltd. Methods and compositions using protein binding partners
CN1300772A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人酸性核糖体磷蛋白16和编码这种多肽的多核苷酸
US6673351B1 (en) 2001-03-16 2004-01-06 Astralis, Llc Compositions and methods for the treatment and clinical remission of psoriasis
US20040241168A1 (en) * 2001-03-16 2004-12-02 O'daly Jose A. Compositions and methods for the treatment and clinical remission of psoriasis
EP1711520B1 (en) 2003-12-26 2010-02-10 All India Institute of Medical Sciences Polypeptides for the diagnosis and therapy of leishmaniasis
WO2006060737A2 (en) * 2004-12-03 2006-06-08 Takeda San Diego, Inc. Mitotic kinesin inhibitors
WO2007081779A2 (en) * 2006-01-05 2007-07-19 Genentech, Inc. Methods of determining cutoff points
US7833534B2 (en) 2006-04-10 2010-11-16 Infectious Disease Research Institute Compounds and methods for diagnosis and treatment of leishmaniasis
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2068918T5 (pl) 2006-09-26 2024-12-02 Access To Advanced Health Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
US7831108B2 (en) 2006-12-13 2010-11-09 Adobe Systems Incorporated Universal front end for masks, selections, and paths
AR073452A1 (es) 2008-07-03 2010-11-10 Infectious Disease Res Inst Proteinas de fusion que comprende dos o mas antigenos de leishmania y su uso en el diagnostico y tratamiento de leishmaniasis
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
AP3516A (en) * 2009-07-13 2016-01-11 Leti Sl Lab Diagnosis of a parasitic disease such as leishmaniasis using ribosomal protein extract (rpe)
US8406566B1 (en) 2010-05-27 2013-03-26 Adobe Systems Incorporated Methods and apparatus for soft edge masking
BRPI1003744B1 (pt) * 2010-06-08 2021-10-26 Universidade Federal De Ouro Preto E-ntpdases recombinantes, uso na produção de kit de diagnóstico para detecção de anticorpos nas leishmanioses causadas por espécies do gênero leishmania
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
HRP20181102T1 (hr) 2012-05-16 2018-09-07 Immune Design Corp Cjepiva za hsv-2
EP2978447B1 (en) 2013-03-28 2019-05-08 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
MX370573B (es) 2013-04-18 2019-12-17 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
KR20250008135A (ko) 2016-06-01 2025-01-14 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
CA3141577A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3581288D1 (de) * 1984-10-01 1991-02-14 Pasteur Institut Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
IL82740A0 (en) * 1987-06-01 1987-12-20 Yeda Res & Dev Assay for leishmaniasis
FR2619220B1 (fr) * 1987-08-03 1993-03-26 Pasteur Institut Antigenes specifiques de leishmania et leur procede de preparation, profils antigeniques contenant ces antigenes et leur application au diagnostic des leishmanioses viscerales.
US5304371A (en) * 1992-02-14 1994-04-19 Lasys Corporation Peptide for diagnosing and immunizing against T. cruzi infection
US5411865A (en) * 1993-01-15 1995-05-02 Iasys Corporation Method of detecting anti-leishmania parasite antibodies

Also Published As

Publication number Publication date
EP1179733A1 (en) 2002-02-13
WO1996033414A2 (en) 1996-10-24
WO1996033414A3 (en) 1996-11-21
MX9708121A (es) 1998-06-30
EP0824699A2 (en) 1998-02-25
DE69616777D1 (de) 2001-12-13
EP0824699B1 (en) 2001-11-07
ATE208500T1 (de) 2001-11-15
US5912166A (en) 1999-06-15
PT824699E (pt) 2002-04-29
BR9608016A (pt) 1999-03-02
AU5559496A (en) 1996-11-07

Similar Documents

Publication Publication Date Title
ES2164883T3 (es) Compuestos y metodos para la diagnosis de la leishmaniasis.
ES2180754T3 (es) Compuestos y metodos para la deteccion de infeccion por t. cruzi.
AR019818A1 (es) Un inmunoconjugado de miostatina.
BR9814473A (pt) Imunógenos anti-retrovirais, preparação e uso
BR0112602A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
BG95337A (bg) Ваксиниране и методи срещу заболявания,резултат от патогенни отговори на т-клетъчно специфични популации
BR0016066A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
ES2166779T3 (es) Complejos inmunogenicos del hiv.
FI902143A0 (fi) Hiv-peptider, artificiella hiv -antigener och immunobestaemningsfoerpackningar.
ATE284710T1 (de) Adjuvans für vitale impfstoffe
PT98156A (pt) Um processo de preparacao de uma composicao de vacina
ES2074062T3 (es) Inmunoensayo para antigenos hiv-1 que utilizan fragmentos de f(ab')2 como sonda.
PT854924E (pt) Antigenios de leishmania para uso na terapia e diagnostico da leishmaniose
Dunan et al. Vaccination trial against canine visceral leishmaniasis
IT8248474A0 (it) Antigene anti-malarico, procedimento per la sua preparazione e vaccino che lo contiene
IT1229669B (it) Procedimento per la preparazione di metacrilati di alcooli fluorurati.
ES2053712T3 (es) Un antigeno proteico reactivo y fragmentos del mismo.
IT8521718A0 (it) Composizione peptidica utile per la preparazione di vaccini per la malaria e di kit diagnostici per la determinazione di affezioni malariche.
ES2118720T3 (es) Produccion y utilizacion de agentes antihelminticos e inmunogenos protectores.
ES2089607T3 (es) Procedimiento para la obtencion de 1-fluorciclopropil-metil-cetona.
ES2059305T5 (es) Proteina del virus de la seudorrabia.
BR0009077A (pt) Antìgenos de tuberculose e métodos de uso dos mesmos
ES8604693A1 (es) Un metodo para detectar un anticuerpo o un antigeno contenido en una muestra de fluido de origen biologico.
DK138886A (da) Anaplasma marginale-antigen eller fragmenter heraf til anvendelse ved vaccination eller diagnose samt vaccine, der indeholder dette
ES2308850T3 (es) Anticuerpos para antigenos de celulas de langerhans de mamiferos y sus usos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 824699

Country of ref document: ES